An emerging antiarrhythmic target: Late sodium current

T. Banyasz, N. Szentandrássy, J. Magyar, Z. Szabo, P. P. Nánási, Ye Chen-Izu, Leighton T Izu

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The cardiac late sodium current (INa,L) has been in the focus of research in the recent decade. The first reports on the sustained component of voltage activated sodium current date back to the seventies, but early studies interpreted this tiny current as a product of a few channels that fail to inactivate, having neither physiologic nor pathologic implications. Recently, the cardiac INa,L has emerged as a potentially major arrhythmogenic mechanism in various heart diseases, attracting the attention of clinicians and researchers. Research activity on INa,L has exponentially increased since Ranolazine, an FDA-approved antianginal drug was shown to successfully suppress cardiac arrhythmias by inhibiting INa,L. This review aims to summarize and discuss a series of papers focusing on the cardiac late sodium current and its regulation under physiological and pathological conditions. We will discuss critical evidences implicating INa,L as a potential target for treating myocardial dysfunction and cardiac arrhythmias.

Original languageEnglish (US)
Pages (from-to)1073-1090
Number of pages18
JournalCurrent Pharmaceutical Design
Volume21
Issue number8
StatePublished - Jan 1 2015

    Fingerprint

Keywords

  • Arrhythmias
  • Cardiac sodium channel
  • Late sodium current

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Banyasz, T., Szentandrássy, N., Magyar, J., Szabo, Z., Nánási, P. P., Chen-Izu, Y., & Izu, L. T. (2015). An emerging antiarrhythmic target: Late sodium current. Current Pharmaceutical Design, 21(8), 1073-1090.